The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
Dividend-paying stocks are a traditional defensive play, while healthcare faces fewer trade and economic headwinds than most ...
Celonic Integrates Merck’s Breez Micro-Bioreactor Platform Into Its Process Development Operations
The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...
OUSA is an ETF that provides exposure to high-quality U.S. companies that pay regular dividends. The fund tracks the O’Shares ...
What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...
The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Their CryptoMap platform leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of ...
The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...
AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and ...
DelveInsight's In Situ Hybridization Market Insights report provides the current and forecast market analysis, individual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback